Revenio Group Oyj
Do you own Revenio Group, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Revenio Group and a few more. Free, no card.
In short
- Revenio Group has risen 6.9% over the past year, including dividends.
- The largest fall over the past three years was 4.0%. The price is 1.2% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns–
- Return on equityProfit divided by equity–
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
- P/BPrice divided by equity–
- P/SPrice divided by sales–
- P/EPrice divided by earnings–
- P/CFPrice divided by operating cash flow–
The ranking is built on P/E, P/B and P/S.
- 3 months+6.9%
- 6 months+6.9%
- 9 months–
- 12 months+6.9%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Revenio Group
The share trades in EUR. It has around 760 employees.
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients.
See the full analysis of Revenio Group.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card